ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3170

Association Between Insulin Resistance, Subclinical Artheriosclerosis and Activity/Damage Status in Systemic Lupus Erythematosus Patients

Hiurma Sanchez-Perez1, Beatriz Tejera2 and Ivan Ferraz-Amaro3, 1Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna, Spain, 2Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 3Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, Tenerife, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Activity score, insulin resistance, intima medial thickness and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 16, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment V: Damage and Morbidity

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose:  Insulin resistance (IR) may contribute to an increase in cardiovascular risk. The aim of this study was to examine the association between IR and disease activity, disease phenotypes, drug exposure and subclinical atherosclerosis in patients with SLE.

Methods:  Cross-sectional study that encompassed 332 non-diabetes individuals; 102 SLE patients and 220 age/sex-matched controls. IR by homeostatic model assessment (HOMA2), insulin, C-peptide serum levels and lipid profile were assessed in both groups. Activity (SLEDAI), severity (Katz) and damage (SLICC) scores, carotid intima-media thickness (cIMT) and carotid plaques were assessed in SLE patients. A multivariable regression analysis, adjusted for IR related factors, was performed to evaluate the differences between groups in IR indexes and, in SLE patients, the interrelation between IR and disease activity/characteristics.

Results:  Median disease duration was 16 (IQR 9-28) years. Body mass index and abdominal circumference did not differ between groups. HOMA-IR-C-peptide (mean difference [IQR], 1.26 [0.77-1.74], p=0.00) and HOMA-%B-C-peptide (56 [4-71], p=0.00) were increased in SLE patients compared to controls. Similarly, insulin sensitivity through HOMA-S% was inferior in SLE patients (-44 [-28-61], p=0.00). Forty percent of patients were in no activity SLEDAI score, while 32, 21 and 9% were in mild, moderate and high/very high activity respectively. Patients in the SLEDAI high or very high activity category disclosed a higher HOMA-IR level (4.8 ± 4.8 vs. 2.07 ± 1.40, p= 0.00) when compared to those in the no activity category. SLICC index was also clearly associated with IR indexes; higher index values were related with higher HOMA-IR (beta coef. 0.27 [0.08-0.46], p=0.01) and lower HOMA-S% (beta coef. -6 [-10–3], p=0.00) levels. These associations remained significant after adjustment for age, gender, smoking, hypertension, and dyslipidemia. Katz severity index did not revealed relation with IR indexes. Use of prednisone was positively associated with HOMA-IR both when it was considered binary (beta coef 1.75 [1.37-2.12], p=0.00) and continuous (beta coef 0.15 [0.07-0.23] per mg, p=0.00). Hydroxychloroquine/other DMARDs use was not related with IR indexes. Patients with higher anti-DNA titers and those with lower complement serum levels did not reach higher IR levels. 28% of the SLE patients had carotid plaques. The presence of carotid plaque was associated with higher HOMA-IR-C-peptide (3.75 ± 3.62 vs. 1.86-1.19, p=0.00). This difference remained significant after adjustment for demographics or cardiometabolic risk factors (1.50 [0.34-2.66], p=0.01).

Conclusion: IR is present in a significant proportion of SLE patients. Disease activity and damage are SLE-related factors that lead to IR development IR is independently associated with subclinical artheriosclerosis in SLE patients.


Disclosure: H. Sanchez-Perez, None; B. Tejera, None; I. Ferraz-Amaro, None.

To cite this abstract in AMA style:

Sanchez-Perez H, Tejera B, Ferraz-Amaro I. Association Between Insulin Resistance, Subclinical Artheriosclerosis and Activity/Damage Status in Systemic Lupus Erythematosus Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/association-between-insulin-resistance-subclinical-artheriosclerosis-and-activitydamage-status-in-systemic-lupus-erythematosus-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-insulin-resistance-subclinical-artheriosclerosis-and-activitydamage-status-in-systemic-lupus-erythematosus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology